Year-end Report 2017

Strategic decisions, collaboration agreements and financing Xintela took major steps forward in 2017 and there is every reason to be optimistic about the new year. Our unique stem cell technology and the decision to establish our own GMP facility for stem cell production have made us a player to reckon with in regenerative medicine. We […]

Newsletter no 6 2017

Another year is coming to a close, and it has been an intensive one involving several important decisions and events. Construction of our own production facility for stem cells was one key decision that demonstrates that Xintela is advancing strongly in the field of regenerative medicine. The fact that Xintela has now taken this step […]

Xintela licenses human antibody technology for cancer therapy

Xintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela’s markers integrin 101 och integrin 111, are already adapted for human use. This means that Xintela saves both time and money and that Xintela’s cancer products can be tested […]

Xintela to collaborate with Japanese CellSeed Inc.

Xintela AB (publ) announces today that the company has signed a collaboration agreement with the leading Japanese cell therapy company, CellSeed, for its development of a cell therapy product for the treatment of cartilage damage in the knee joint. “It is very exciting that we have established a collaboration in Japan which, due to a […]

Xintela raises 17 million SEK in debt and equity

Xintela AB (publ) announces a directed share issue of approximately 10 million SEK and borrowing of 7 million SEK to strengthen its working capital for investment in Xintela’s development programs. The Board of Xintela, under the authorization adopted at the AGM on 18 May 2017, today decided to issue a total of 3,205,129 new shares, […]

Keld Søndergaard leaves Xintela’s Board of Directors

Xintela AB (publ) announces that Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons. Xintela’s larger shareholders, acting as an informal nomination committee, will consider potential replacement candidates to propose to the next Annual General Meeting. Keld Søndergaard was elected as a new member of the Board at the Annual General […]

Newsletter no 5 2017

Xintela has now taken a big step forward in the stem cell project by initiating the construction of its own GMP manufacturing facility for the production of horse as well as human stem cells. This is an important step for Xintela, which shows that our strategy is to become a complete and competitive company in […]

Xintela building own GMP-facility for stem cell production

Xintela AB (publ) announces the company has decided to bring forward the construction of its own facility for production of equine and human stem cell-based ATMPs (Advanced Therapy Medicinal Products) at Medicon Village, Lund. Initially, stem cells will be produced for clinical studies in horses. After careful evaluation of available options, Xintela has decided to […]